Patients with COVID-19 pneumonia with 25(OH)D levels lower than 12 ng/ml are at increased risk of death.
COVID-19
Vitamin D
mortality
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
07
12
2021
revised:
17
01
2022
accepted:
18
01
2022
pubmed:
26
1
2022
medline:
3
3
2022
entrez:
25
1
2022
Statut:
ppublish
Résumé
There is no consensus on specific serum 25-hydroxy vitamin D (25(OH) D) levels associated with higher risk of severe outcome in patients with coronavirus disease 2019 (COVID-19). According to the literature patients with serum 25(OH) D levels <12 ng/ml are clearly deficient at all ages. Our aim was to assess COVID-19 mortality in the settings of severe 25(OH) D deficiency. A cohort study of 357 patients with COVID-19 was conducted. Subjects were monitored until discharge or in-hospital death. At admission, severity parameters (C-reactive protein (CRP), IL-6, Charlson comorbidity index, etc.) were assessed. These parameters were compared regarding 25(OH) D levels threshold 12 ng/ml, where values below 12 ng/ml were considered absolute vitamin D deficiency. 25(OH) D levels at the time of admission were independently associated with mortality (p <0.05). Nonsurvivors (N = 168) had lower 25(OH) D levels, SO2, higher age, CRP, viral load, and Charlson comorbidity index in comparison to survivors. Patients with serum 25(OH) D levels <12 ng/ml had higher mortality (55% vs 45 %), viral load (21.5 vs 23.1), and Charlson comorbidity index (5.3 vs 4.4) than those with serum 25(OH) D levels >12 ng/ml (p <0.05). Patients with COVID-19 with serum 25(OH) D levels <12 ng/ml have higher mortality. Among other factors, severe vitamin D deficiency likely leads to poor outcome.
Identifiants
pubmed: 35077879
pii: S1201-9712(22)00052-2
doi: 10.1016/j.ijid.2022.01.044
pmc: PMC8783398
pii:
doi:
Substances chimiques
Vitamin D
1406-16-2
25-hydroxyvitamin D
A288AR3C9H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
313-318Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest The authors declare that they have no known competing financial interests or personal relationships that could influence the work reported in this paper.
Références
J Med Virol. 2020 Sep;92(9):1580-1586
pubmed: 32249956
Eur J Clin Nutr. 2020 Nov;74(11):1498-1513
pubmed: 31959942
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Eur J Clin Microbiol Infect Dis. 2021 May;40(5):905-919
pubmed: 33389262
Lancet Diabetes Endocrinol. 2020 Sep;8(9):735-736
pubmed: 32758429
Mol Med Rep. 2017 Nov;16(5):7432-7438
pubmed: 28944831
Nutrients. 2020 Apr 02;12(4):
pubmed: 32252338
J Med Virol. 2021 Sep;93(9):5285-5294
pubmed: 33990955
Nutr J. 2021 Oct 31;20(1):89
pubmed: 34719404
Front Pharmacol. 2021 Apr 20;12:667254
pubmed: 33959029
Lancet Rheumatol. 2020 Dec;2(12):e754-e763
pubmed: 33015645
Calcif Tissue Int. 2020 Jan;106(1):14-29
pubmed: 31069443
Crit Rev Food Sci Nutr. 2022;62(5):1308-1316
pubmed: 33146028
Metabolism. 2021 Feb;115:154434
pubmed: 33217408
Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):2131-2145
pubmed: 33660833
Postgrad Med J. 2021 Jul;97(1149):442-447
pubmed: 32855214
JAMA. 2021 Mar 16;325(11):1053-1060
pubmed: 33595634
Clin Endocrinol (Oxf). 2012 Mar;76(3):315-25
pubmed: 21995874
Vitam Horm. 2011;86:217-37
pubmed: 21419273
JBMR Plus. 2020 Sep 15;5(1):e10405
pubmed: 32904944
Eur J Endocrinol. 2019 Apr;180(4):P23-P54
pubmed: 30721133
Rev Endocr Metab Disord. 2020 Mar;21(1):89-116
pubmed: 32180081
BMJ. 2017 Feb 15;356:i6583
pubmed: 28202713